Different therapeutic regimens in the treatment of metastatic prostate cancer by performing a Bayesian network meta-analysis
- 1 June 2019
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 66, 28-36
Abstract
Although androgen deprivation therapy with or without chemotherapy are currently the mainstay of therapy for metastatic prostate cancer, accumulating data suggested the survival benefits from definitive local therapy such as radical prostatectomy or radiation therapy. Hence, this network meta-analysis was aimed to provide a hierarchy of different therapeutic regimens for mPCa. Relevant studies were retrieved comprehensively by searching the online databases of PubMed, EMBASE and Web of Science, published before July 1st, 2018. With the help of R-3.4.0 software and "gemtc-0.8.2" package, network meta-analysis was performed by random-effect model within a Bayesian framework. Hazard ratios and corresponding 95% credible intervals were calculated by Markov chain Monte Carlo methods. The surface under the cumulative ranking curve was also incorporated to rank the corresponding therapeutic regimens. A total of 55,363 cases from 17 studies were ultimately involved in this study. Ten different therapeutic regimens and three clinical endpoints were finally assessed. As illustrated by our results, local therapy (such as radical prostatectomy or radiation therapy) could provide a relatively more favorable survival rate than systematic therapies (no local therapy, androgen deprivation therapy or androgen deprivation therapy + chemotherapy). Meanwhile, in the comparison of radiation therapy, brachytherapy and intensity modulated radiation therapy were among the best two therapies. Furthermore, radical prostatectomy had a relatively lower cancer specific mortality or all-cause mortality than brachytherapy or intensity modulated radiation therapy, in the comparison of local therapy, whereas brachytherapy showed a relatively longer overall survival than radical prostatectomy. Our results indicated that local therapy was better than no local therapy. In a comprehensive comparison of three clinical endpoints (overall survival, cancer specific mortality or all-cause mortality), radical prostatectomy had a relatively lower cancer specific mortality or all-cause mortality than radiation therapy, whereas brachytherapy was superior to radical prostatectomy for overall survival.Keywords
Funding Information
- Medical key talent of Jiangsu Province (ZDRCA2016009)
- National Natural Science Foundation of China
This publication has 42 references indexed in Scilit:
- Cancer-specific Survival After Metastasis Following Primary Radical Prostatectomy Compared with Radiation Therapy in Prostate Cancer Patients: Results of a Population-based, Propensity Score–Matched AnalysisEuropean Urology, 2014
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Phase III Trial of Androgen Ablation With or Without Three Cycles of Systemic Chemotherapy for Advanced Prostate CancerJournal of Clinical Oncology, 2008
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice GuidelineJournal of Clinical Oncology, 2007
- Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermiaThe Lancet Oncology, 2004
- Aggregate data meta‐analysis with time‐to‐event outcomesStatistics in Medicine, 2002
- Impact of Previous Local Treatment for Prostate Cancer on Subsequent Metastatic DiseaseJournal of Urology, 2002
- Need for Hospital Care and Palliative Treatment for Prostate Cancer Treated with Noncurative IntentJournal of Urology, 1995
- Inference from Iterative Simulation Using Multiple SequencesStatistical Science, 1992